Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription coactivator activity	TGFB1I1 ABL1 FIZ1 MAML1 SMARCA2 MAML2 KAT2A BCL9 HCFC1	7.86e-08	303	52	9	GO:0003713
GeneOntologyMolecularFunction	transcription coregulator activity	TGFB1I1 ABL1 FIZ1 MAML1 SMARCA2 MAML2 KAT2A BCL9 HCFC1 SF1	1.57e-06	562	52	10	GO:0003712
GeneOntologyMolecularFunction	transcription factor binding	TGFB1I1 TAF3 FIZ1 KAT2A TAF4 BSN HCFC1 TP53	6.82e-04	753	52	8	GO:0008134
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	TGFB1I1 ABL1 FIZ1 MAML1 SMARCA2 MAML2 KAT2A BCL9 HCFC1 SF1	7.12e-04	1160	52	10	GO:0030674
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	TAF3 ABL1 PTF1A FIZ1 MAML1 SMARCA2 POU2F2 MAML2 KAT2A TAF4 BCL9 HCFC1 TP53	2.38e-05	1390	51	13	GO:0045944
GeneOntologyCellularComponent	chromatin	UNCX PTF1A BICRA HES7 FIZ1 SMARCA2 ZFHX2 POU2F2 KAT2A TAF4 HCFC1 TP53	2.20e-04	1480	52	12	GO:0000785
GeneOntologyCellularComponent	GBAF complex	BICRA SMARCA2	5.42e-04	14	52	2	GO:0140288
GeneOntologyCellularComponent	RNA polymerase II transcription regulator complex	TAF3 KAT2A TAF4 BCL9 TP53	5.67e-04	272	52	5	GO:0090575
GeneOntologyCellularComponent	transcription factor TFTC complex	KAT2A TAF4	9.05e-04	18	52	2	GO:0033276
GeneOntologyCellularComponent	RNA polymerase II, holoenzyme	TAF3 KAT2A TAF4	1.42e-03	89	52	3	GO:0016591
GeneOntologyCellularComponent	histone acetyltransferase complex	KAT2A TAF4 HCFC1	1.66e-03	94	52	3	GO:0000123
GeneOntologyCellularComponent	myosin II complex	MYL1 MYL4	2.20e-03	28	52	2	GO:0016460
GeneOntologyCellularComponent	protein acetyltransferase complex	KAT2A TAF4 HCFC1	2.21e-03	104	52	3	GO:0031248
GeneOntologyCellularComponent	SWI/SNF complex	BICRA SMARCA2	2.52e-03	30	52	2	GO:0016514
GeneOntologyCellularComponent	acetyltransferase complex	KAT2A TAF4 HCFC1	2.53e-03	109	52	3	GO:1902493
GeneOntologyCellularComponent	extrinsic component of membrane	CISH APC2 BSN RPH3A	2.56e-03	230	52	4	GO:0019898
GeneOntologyCellularComponent	germ cell nucleus	TAF3 TAF4 TP53	2.80e-03	113	52	3	GO:0043073
GeneOntologyCellularComponent	nuclear DNA-directed RNA polymerase complex	TAF3 KAT2A TAF4	2.80e-03	113	52	3	GO:0055029
GeneOntologyCellularComponent	MLL1 complex	TAF4 HCFC1	2.87e-03	32	52	2	GO:0071339
GeneOntologyCellularComponent	DNA-directed RNA polymerase complex	TAF3 KAT2A TAF4	3.02e-03	116	52	3	GO:0000428
GeneOntologyCellularComponent	MLL1/2 complex	TAF4 HCFC1	3.05e-03	33	52	2	GO:0044665
GeneOntologyCellularComponent	RNA polymerase complex	TAF3 KAT2A TAF4	3.24e-03	119	52	3	GO:0030880
GeneOntologyCellularComponent	transcription regulator complex	TAF3 PTF1A KAT2A TAF4 BCL9 TP53	3.50e-03	596	52	6	GO:0005667
GeneOntologyCellularComponent	SAGA-type complex	KAT2A TAF4	4.24e-03	39	52	2	GO:0070461
Domain	Neuroggenic_mastermind-like_N	MAML1 MAML2	2.19e-05	3	51	2	IPR019082
Domain	MamL-1	MAML1 MAML2	2.19e-05	3	51	2	PF09596
Domain	MamL-1	MAML1 MAML2	2.19e-05	3	51	2	SM01275
Domain	Znf_FYVE_PHD	TAF3 BSN FGD6 RPH3A	6.91e-04	147	51	4	IPR011011
Domain	Bromodomain_CS	SMARCA2 KAT2A	2.28e-03	26	51	2	IPR018359
Domain	SH3	ABL1 CASKIN1 OBSCN ARHGAP33	2.84e-03	216	51	4	SM00326
Domain	SH3	ABL1 CASKIN1 OBSCN ARHGAP33	2.84e-03	216	51	4	PS50002
Domain	SH3_domain	ABL1 CASKIN1 OBSCN ARHGAP33	3.04e-03	220	51	4	IPR001452
Domain	Znf_FYVE-rel	FGD6 RPH3A	3.88e-03	34	51	2	IPR017455
Domain	BROMODOMAIN_1	SMARCA2 KAT2A	4.58e-03	37	51	2	PS00633
Domain	Znf_FYVE	FGD6 RPH3A	4.83e-03	38	51	2	IPR000306
Domain	Bromodomain	SMARCA2 KAT2A	4.83e-03	38	51	2	PF00439
Domain	ZF_FYVE	FGD6 RPH3A	5.34e-03	40	51	2	PS50178
Domain	BROMODOMAIN_2	SMARCA2 KAT2A	5.60e-03	41	51	2	PS50014
Domain	BROMO	SMARCA2 KAT2A	5.87e-03	42	51	2	SM00297
Domain	Bromodomain	SMARCA2 KAT2A	5.87e-03	42	51	2	IPR001487
Domain	-	SMARCA2 KAT2A	5.87e-03	42	51	2	1.20.920.10
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML1 MAML2 KAT2A	2.32e-06	10	39	3	MM15535
Pathway	REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	PTF1A MAML1 MAML2 KAT2A	5.19e-06	42	39	4	M17541
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML1 MAML2 KAT2A	6.98e-06	14	39	3	M27808
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	MAML1 MAML2 KAT2A	1.07e-05	16	39	3	M27121
Pathway	REACTOME_SIGNALING_BY_NOTCH1	MAML1 MAML2 KAT2A	1.55e-05	18	39	3	MM14775
Pathway	REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 MAML2 KAT2A	2.16e-05	20	39	3	M27881
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	MAML1 MAML2 KAT2A	3.34e-05	23	39	3	MM14954
Pathway	REACTOME_FORMATION_OF_PARAXIAL_MESODERM	HES7 MAML1 MAML2 KAT2A	3.80e-05	69	39	4	M46439
Pathway	REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 MAML2 KAT2A	4.32e-05	25	39	3	M27880
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	MAML1 MAML2 KAT2A TP53	5.56e-05	76	39	4	MM15520
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	MAML1 MAML2 KAT2A	6.11e-05	28	39	3	M6177
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	MAML1 MAML2 KAT2A TP53	1.38e-04	96	39	4	M27784
Pathway	WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY	SALL3 SMARCA2 CABIN1 HCFC1 SF1 TP53	1.62e-04	301	39	6	MM15983
Pathway	REACTOME_SIGNALING_BY_NOTCH	MAML1 MAML2 KAT2A	1.67e-04	39	39	3	MM14604
Pathway	KEGG_NOTCH_SIGNALING_PATHWAY	MAML1 MAML2 KAT2A	2.92e-04	47	39	3	M7946
Pathway	PID_HES_HEY_PATHWAY	PTF1A MAML1 MAML2	3.11e-04	48	39	3	M288
Pathway	REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 MAML2 KAT2A	3.11e-04	48	39	3	M611
Pathway	REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING	MAML1 MAML2 KAT2A TP53	3.16e-04	119	39	4	M607
Pathway	REACTOME_SIGNALING_BY_NOTCH3	MAML1 MAML2 KAT2A	3.30e-04	49	39	3	M618
Pathway	REACTOME_GASTRULATION	HES7 MAML1 MAML2 KAT2A	4.30e-04	129	39	4	M46433
Pathway	REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 MAML2	4.84e-04	12	39	2	M27159
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00380	MAML1 MAML2	4.84e-04	12	39	2	M47532
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00381	MAML1 MAML2	4.84e-04	12	39	2	M47533
Pathway	REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER	MAML1 MAML2 KAT2A	5.44e-04	58	39	3	M29616
Pathway	REACTOME_RHOQ_GTPASE_CYCLE	OBSCN ARHGAP33 CDC42EP1	5.44e-04	58	39	3	MM15602
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00382	MAML1 MAML2	5.71e-04	13	39	2	M47534
Pathway	REACTOME_RHOQ_GTPASE_CYCLE	OBSCN ARHGAP33 CDC42EP1	5.72e-04	59	39	3	M41812
Pathway	REACTOME_FORMATION_OF_SENESCENCE_ASSOCIATED_HETEROCHROMATIN_FOCI_SAHF	CABIN1 TP53	7.65e-04	15	39	2	MM14902
Pathway	BIOCARTA_ARF_PATHWAY	ABL1 TP53	8.73e-04	16	39	2	MM1524
Pathway	REACTOME_FORMATION_OF_SENESCENCE_ASSOCIATED_HETEROCHROMATIN_FOCI_SAHF	CABIN1 TP53	9.88e-04	17	39	2	M27189
Pathway	BIOCARTA_ARF_PATHWAY	ABL1 TP53	9.88e-04	17	39	2	M11358
Pathway	REACTOME_SIGNALING_BY_NOTCH1	MAML1 MAML2 KAT2A	1.11e-03	74	39	3	M616
Pathway	WP_TP53_NETWORK	ABL1 TP53	1.24e-03	19	39	2	M39368
Pathway	BIOCARTA_ATM_PATHWAY	ABL1 TP53	1.24e-03	19	39	2	MM1351
Pathway	BIOCARTA_ATM_PATHWAY	ABL1 TP53	1.37e-03	20	39	2	M10628
Pathway	REACTOME_SIGNALING_BY_NOTCH4	MAML1 MAML2 KAT2A	1.49e-03	82	39	3	M594
Pathway	WP_DELTANOTCH_SIGNALING_PATHWAY	MAML1 MAML2 TP53	1.49e-03	82	39	3	MM15922
Pathway	REACTOME_GENE_EXPRESSION_TRANSCRIPTION	TAF3 ABL1 MAML1 POU2F2 MAML2 KAT2A TAF4 HCFC1 TP53	1.56e-03	1022	39	9	MM15436
Pathway	WP_RETINOBLASTOMA_GENE_IN_CANCER	ABL1 SMARCA2 TP53	1.95e-03	90	39	3	M39678
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_PHOSPHORYLATION	TAF3 TAF4 TP53	2.07e-03	92	39	3	M27636
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_PHOSPHORYLATION	TAF3 TAF4 TP53	2.07e-03	92	39	3	MM15338
Pathway	KEGG_MEDICUS_REFERENCE_DEUBIQUITINATION_OF_H2AK119	MBD6 HCFC1	2.32e-03	26	39	2	M47923
Pathway	WP_CANONICAL_AND_NONCANONICAL_NOTCH_SIGNALING	MAML1 MAML2	2.51e-03	27	39	2	M39545
Pathway	BIOCARTA_G1_PATHWAY	ABL1 TP53	2.69e-03	28	39	2	M648
Pathway	BIOCARTA_G1_PATHWAY	ABL1 TP53	2.89e-03	29	39	2	MM1364
Pathway	REACTOME_SIGNALING_BY_NOTCH2	MAML1 MAML2	3.73e-03	33	39	2	M604
Pubmed	Human transcription factor protein interaction networks.	TAF3 UBE2O BICRA PRRC2C MAML1 SMARCA2 C15orf39 KAT2A TAF4 MAP7 BCL9 MBD6 CABIN1 HCFC1 TP53 SCAF4	1.55e-10	1429	52	16	35140242
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	UNCX BICRA PRRC2C MAML1 SMARCA2 C15orf39 KAT2A TAF4 BCL9 HCFC1 SF1 TP53 SCAF4	6.17e-09	1103	52	13	34189442
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	ABL1 IER5L BICRA CASKIN1 OBSCN MAML1 C15orf39 KAT2A BCL9 MBD6 CABIN1 HCFC1 ARHGAP33	6.30e-09	1105	52	13	35748872
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	TBC1D10B TAF3 BICRA FIZ1 SMARCA2 STK39 ABHD8 KAT2A TAF4 MAP7 TP53 ARHGAP33 CDC42EP1	7.09e-09	1116	52	13	31753913
Pubmed	The TAF10-containing TFIID and SAGA transcriptional complexes are dispensable for early somitogenesis in the mouse embryo.	CDKN1C TAF3 UNCX HES7 TAF4	1.51e-08	52	52	5	28893950
Pubmed	Interaction network of human early embryonic transcription factors.	TAF3 BICRA MAML1 SMARCA2 C15orf39 TAF4 BCL9 MBD6	5.08e-08	351	52	8	38297188
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	UBE2O PRR36 PRRC2C CASKIN1 APC2 CNTNAP1 TAF4 BSN BCL9 CABIN1 RPH3A	1.48e-07	963	52	11	28671696
Pubmed	Mastermind-like 1 (MamL1) and mastermind-like 3 (MamL3) are essential for Notch signaling in vivo.	UNCX MAML1 MAML2	1.74e-06	16	52	3	22069191
Pubmed	Cabin1 restrains p53 activity on chromatin.	CABIN1 TP53	2.19e-06	2	52	2	19668210
Pubmed	Insights into selective activation of p53 DNA binding by c-Abl.	ABL1 TP53	2.19e-06	2	52	2	15661746
Pubmed	Brm inhibits the proliferative response of keratinocytes and corneal epithelial cells to ultraviolet radiation-induced damage.	SMARCA2 TP53	2.19e-06	2	52	2	25254962
Pubmed	HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.	POU2F2 HCFC1	2.19e-06	2	52	2	27009953
Pubmed	Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.	ABL1 TP53	2.19e-06	2	52	2	10629029
Pubmed	TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function.	TAF3 TP53	2.19e-06	2	52	2	18549481
Pubmed	The effects of c-Abl mutation on developing B cell differentiation and survival.	ABL1 TP53	2.19e-06	2	52	2	19299624
Pubmed	CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.	CISH ABL1	2.19e-06	2	52	2	11274764
Pubmed	p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling.	ABL1 TP53	2.19e-06	2	52	2	16380437
Pubmed	c-Abl: activation and nuclear targets.	ABL1 TP53	2.19e-06	2	52	2	10713716
Pubmed	Abl1 deletion in gut stem cells suppresses p53 induction and promotes colitis-associated tumor formation.	ABL1 TP53	2.19e-06	2	52	2	32652042
Pubmed	Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.	ABL1 TP53	2.19e-06	2	52	2	28661474
Pubmed	c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.	ABL1 TP53	2.19e-06	2	52	2	10805805
Pubmed	Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity.	ABL1 TP53	2.19e-06	2	52	2	23660976
Pubmed	Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression.	TAF3 TAF4 TP53	2.53e-06	18	52	3	15053879
Pubmed	Deregulation of the p57-E2F1-p53 axis results in nonobstructive hydrocephalus and cerebellar malformation in mice.	CDKN1C PTF1A TP53	3.00e-06	19	52	3	21844226
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	BICRA MAML1 C15orf39 BCL9 SF1	3.29e-06	152	52	5	38360978
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	TGFB1I1 BICRA APC2 MAML2 BSN BCL9 TP53	3.48e-06	430	52	7	35044719
Pubmed	Supt20 is required for development of the axial skeleton.	UNCX HES7 KAT2A	4.11e-06	21	52	3	27894818
Pubmed	Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling.	MAML1 MAML2	6.57e-06	3	52	2	12386158
Pubmed	Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.	PTF1A TP53	6.57e-06	3	52	2	36384095
Pubmed	Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.	PTF1A TP53	6.57e-06	3	52	2	30696657
Pubmed	Involvement of c-Abl, p53 and the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 cells by exposure to blue light.	ABL1 TP53	6.57e-06	3	52	2	19052872
Pubmed	Meiotic telomere distribution and Sertoli cell nuclear architecture are altered in Atm- and Atm-p53-deficient mice.	ABL1 TP53	6.57e-06	3	52	2	11003672
Pubmed	Light chains from fast and slow muscle myosins.	MYL1 MYL4	6.57e-06	3	52	2	4942892
Pubmed	mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.	PTF1A TP53	6.57e-06	3	52	2	27758884
Pubmed	Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression.	PTF1A TP53	6.57e-06	3	52	2	36614194
Pubmed	Role of the nerve in determining fetal skeletal muscle phenotype.	MYL1 MYL4	6.57e-06	3	52	2	9489771
Pubmed	Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress.	ABL1 TP53	6.57e-06	3	52	2	18490454
Pubmed	Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.	PTF1A TP53	6.57e-06	3	52	2	25977335
Pubmed	Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.	ABL1 TP53	6.57e-06	3	52	2	12110584
Pubmed	Myosin light chain gene expression in developing and denervated fetal muscle in the mouse.	MYL1 MYL4	6.57e-06	3	52	2	2534378
Pubmed	MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.	PTF1A TP53	6.57e-06	3	52	2	22761793
Pubmed	Modifying transcript lengths of cycling mouse segmentation genes.	UNCX HES7	6.57e-06	3	52	2	22326607
Pubmed	Promoter analysis of myosin alkali light chain genes expressed in mouse striated muscle.	MYL1 MYL4	6.57e-06	3	52	2	3194193
Pubmed	Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer.	PTF1A TP53	6.57e-06	3	52	2	31043430
Pubmed	Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.	PTF1A TP53	6.57e-06	3	52	2	22084065
Pubmed	IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.	PTF1A TP53	6.57e-06	3	52	2	23603816
Pubmed	c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.	ABL1 TP53	6.57e-06	3	52	2	27626309
Pubmed	Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice.	PTF1A TP53	6.57e-06	3	52	2	31490946
Pubmed	Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance.	KAT2A TP53	6.57e-06	3	52	2	19683498
Pubmed	Trp53 deletion stimulates the formation of metastatic pancreatic tumors.	PTF1A TP53	6.57e-06	3	52	2	18310506
Pubmed	Alkali myosin light chains in man are encoded by a multigene family that includes the adult skeletal muscle, the embryonic or atrial, and nonsarcomeric isoforms.	MYL1 MYL4	6.57e-06	3	52	2	2458299
Pubmed	Dynamic left/right regionalisation of endogenous myosin light chain 3F transcripts in the developing mouse heart.	MYL1 MYL4	6.57e-06	3	52	2	9689582
Pubmed	A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery.	PTF1A TP53	6.57e-06	3	52	2	30224540
Pubmed	p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling.	CDKN1C TP53	6.57e-06	3	52	2	24652995
Pubmed	A modular and flexible ESC-based mouse model of pancreatic cancer.	PTF1A TP53	6.57e-06	3	52	2	24395249
Pubmed	Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion.	PTF1A TP53	6.57e-06	3	52	2	23540692
Pubmed	Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.	ABL1 TP53	6.57e-06	3	52	2	27956626
Pubmed	Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status.	ABL1 TP53	6.57e-06	3	52	2	17409407
Pubmed	The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes.	SMARCA2 TP53	6.57e-06	3	52	2	17938176
Pubmed	c-Abl tyrosine kinase activates p21 transcription via interaction with p53.	ABL1 TP53	6.57e-06	3	52	2	17339230
Pubmed	In Vivo Senescence in the Sbds-Deficient Murine Pancreas: Cell-Type Specific Consequences of Translation Insufficiency.	PTF1A TP53	6.57e-06	3	52	2	26057580
Pubmed	Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion.	PTF1A TP53	6.57e-06	3	52	2	30590101
Pubmed	The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.	ABL1 TP53	6.57e-06	3	52	2	8612582
Pubmed	p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1.	MAML1 TP53	6.57e-06	3	52	2	26033683
Pubmed	The notch regulator MAML1 interacts with p53 and functions as a coactivator.	MAML1 TP53	6.57e-06	3	52	2	17317671
Pubmed	RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas.	CDKN1C TP53	6.57e-06	3	52	2	29661169
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	TAF3 SALL3 BICRA PRRC2C TAF4 HCFC1 SF1 TP53 SCAF4	1.08e-05	954	52	9	36373674
Pubmed	Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta.	ABL1 TP53	1.31e-05	4	52	2	15289456
Pubmed	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.	PTF1A TP53	1.31e-05	4	52	2	29017057
Pubmed	Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression.	PTF1A TP53	1.31e-05	4	52	2	24737325
Pubmed	A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.	PTF1A TP53	1.31e-05	4	52	2	18621715
Pubmed	Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells.	ABL1 TP53	1.31e-05	4	52	2	16636310
Pubmed	Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.	PTF1A TP53	1.31e-05	4	52	2	27637888
Pubmed	Accelerating the tempo of the segmentation clock by reducing the number of introns in the Hes7 gene.	UNCX HES7	1.31e-05	4	52	2	23219549
Pubmed	c-Abl phosphorylates Hdmx and regulates its interaction with p53.	ABL1 TP53	1.31e-05	4	52	2	19075013
Pubmed	SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	36001976
Pubmed	Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	26988419
Pubmed	Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.	PTF1A TP53	1.31e-05	4	52	2	31597100
Pubmed	The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	27649783
Pubmed	Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.	PTF1A TP53	1.31e-05	4	52	2	27376576
Pubmed	Targeting reactive nitrogen species suppresses hereditary pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	28630313
Pubmed	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment.	PTF1A TP53	1.31e-05	4	52	2	32046984
Pubmed	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.	PTF1A TP53	1.31e-05	4	52	2	30355799
Pubmed	Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.	PTF1A TP53	1.31e-05	4	52	2	39037766
Pubmed	Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity.	PTF1A TP53	1.31e-05	4	52	2	39048609
Pubmed	Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.	PTF1A TP53	1.31e-05	4	52	2	21075310
Pubmed	α-Ketoglutarate links p53 to cell fate during tumour suppression.	PTF1A TP53	1.31e-05	4	52	2	31534224
Pubmed	Abl interconnects oncogenic Met and p53 core pathways in cancer cells.	ABL1 TP53	1.31e-05	4	52	2	21455220
Pubmed	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.	PTF1A TP53	1.31e-05	4	52	2	32499547
Pubmed	LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	28475592
Pubmed	Islet amyloid polypeptide does not suppress pancreatic cancer.	PTF1A TP53	1.31e-05	4	52	2	36621763
Pubmed	Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.	ABL1 TP53	1.31e-05	4	52	2	17992189
Pubmed	c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression.	ABL1 TP53	1.31e-05	4	52	2	22729085
Pubmed	Cell of Origin Influences Pancreatic Cancer Subtype.	PTF1A TP53	1.31e-05	4	52	2	34009137
Pubmed	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.	ABL1 TP53	1.31e-05	4	52	2	26295305
Pubmed	Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.	PTF1A TP53	1.31e-05	4	52	2	27546622
Pubmed	Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.	PTF1A TP53	1.31e-05	4	52	2	24803537
Pubmed	Metastatic pancreatic cancer is dependent on oncogenic Kras in mice.	PTF1A TP53	1.31e-05	4	52	2	23226501
Pubmed	Calpain 2 activated through N-methyl-D-aspartic acid receptor signaling cleaves CPEB3 and abrogates CPEB3-repressed translation in neurons.	CPEB3 TP53	1.31e-05	4	52	2	22711986
Pubmed	The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.	PTF1A TP53	1.31e-05	4	52	2	25596178
Interaction	MYOD1 interactions	CDKN1C TAF3 UBE2O SMARCA2 KAT2A BCL9 CABIN1	5.56e-07	194	51	7	int:MYOD1
Interaction	FEV interactions	TAF3 BICRA MAML1 C15orf39 TAF4 BCL9 TP53	7.55e-07	203	51	7	int:FEV
Interaction	TAF9 interactions	TAF3 SMARCA2 KAT2A TAF4 HCFC1 TP53	2.95e-06	159	51	6	int:TAF9
Interaction	EGR2 interactions	BICRA MAML1 SMARCA2 C15orf39 BCL9 HCFC1	4.49e-06	171	51	6	int:EGR2
Interaction	HNF4A interactions	TAF3 BICRA SMARCA2 KAT2A TAF4 CABIN1 TP53	5.66e-06	275	51	7	int:HNF4A
Interaction	HNF1B interactions	BICRA MAML1 SMARCA2 BCL9 MBD6 CABIN1	8.21e-06	190	51	6	int:HNF1B
Interaction	ARHGAP33 interactions	SMARCA2 TP53 ARHGAP33	8.35e-06	16	51	3	int:ARHGAP33
Interaction	CEBPA interactions	UNCX BICRA PRRC2C MAML1 SMARCA2 C15orf39 KAT2A TAF4 BCL9 HCFC1 SF1 TP53 SCAF4	9.40e-06	1245	51	13	int:CEBPA
Interaction	SP7 interactions	BICRA MAML1 SMARCA2 C15orf39 KAT2A BCL9 SCAF4	1.09e-05	304	51	7	int:SP7
Interaction	TOP3B interactions	ABL1 IER5L BICRA CASKIN1 OBSCN MAML1 C15orf39 KAT2A BCL9 MBD6 CABIN1 HCFC1 TP53 ARHGAP33	1.13e-05	1470	51	14	int:TOP3B
Interaction	NOTCH4 interactions	MAML1 MAML2 TP53	1.97e-05	21	51	3	int:NOTCH4
Interaction	ZCCHC10 interactions	TAF3 BICRA SMARCA2 TAF4 CABIN1 TP53	2.81e-05	236	51	6	int:ZCCHC10
Interaction	TAF6 interactions	TAF3 SMARCA2 KAT2A TAF4 HCFC1 TP53	3.46e-05	245	51	6	int:TAF6
Interaction	CRX interactions	BICRA MAML1 SMARCA2 C15orf39 KAT2A BCL9	4.23e-05	254	51	6	int:CRX
Interaction	TLE3 interactions	MYL1 MAML1 C15orf39 TAF4 BCL9 TP53 SCAF4	4.25e-05	376	51	7	int:TLE3
Interaction	TAF4 interactions	TAF3 KAT2A TAF4 HCFC1 TP53	4.59e-05	156	51	5	int:TAF4
Interaction	PPARGC1A interactions	KAT2A HCFC1 SF1 TP53	5.50e-05	82	51	4	int:PPARGC1A
Interaction	SPATA1 interactions	BICRA C15orf39 TP53	6.53e-05	31	51	3	int:SPATA1
Interaction	YAP1 interactions	TGFB1I1 TAF3 UBE2O ABL1 PRRC2C APC2 SMARCA2 TAF4 HCFC1 TP53 SCAF4	7.42e-05	1095	51	11	int:YAP1
Interaction	KAT2A interactions	TAF3 PTF1A KAT2A TAF4 TP53	9.05e-05	180	51	5	int:KAT2A
Interaction	HCFC1 interactions	UBE2O PRRC2C TAF4 MBD6 HCFC1 TP53	9.33e-05	293	51	6	int:HCFC1
Interaction	PPARG interactions	TGFB1I1 ABL1 BICRA SMARCA2 KAT2A TP53	1.20e-04	307	51	6	int:PPARG
Interaction	PRM2 interactions	UBE2O FIZ1 SCAF4	1.31e-04	39	51	3	int:PRM2
Interaction	KLF5 interactions	MAML1 SMARCA2 BCL9 HCFC1 TP53	1.32e-04	195	51	5	int:KLF5
Interaction	YY1 interactions	TAF3 KAT2A TAF4 MBD6 CABIN1 HCFC1 TP53	1.38e-04	454	51	7	int:YY1
Interaction	CISH interactions	CISH TBC1D10B ABL1	1.41e-04	40	51	3	int:CISH
Interaction	E2F1 interactions	CDKN1C SMARCA2 KAT2A HCFC1 TP53	1.48e-04	200	51	5	int:E2F1
Interaction	EP300 interactions	TGFB1I1 ABL1 MAML1 SMARCA2 STK39 MAML2 KAT2A MAP7 BSN SF1 TP53 SCAF4	1.52e-04	1401	51	12	int:EP300
Interaction	TAF10 interactions	TAF3 KAT2A TAF4 TP53	1.55e-04	107	51	4	int:TAF10
Interaction	TAF7 interactions	TAF3 TAF4 HCFC1 TP53	1.61e-04	108	51	4	int:TAF7
Interaction	TAF9B interactions	TAF3 KAT2A TAF4 TP53	1.61e-04	108	51	4	int:TAF9B
Interaction	KLF8 interactions	TAF3 BICRA PRRC2C KAT2A TAF4 MAP7	1.75e-04	329	51	6	int:KLF8
Interaction	ELF4 interactions	TAF3 SMARCA2 KAT2A TAF4	2.04e-04	115	51	4	int:ELF4
Interaction	BRD3 interactions	TBC1D10B TAF3 BICRA SMARCA2 ABHD8 TAF4 TP53	2.32e-04	494	51	7	int:BRD3
Interaction	ERG interactions	BICRA MAML1 SMARCA2 C15orf39 BCL9	2.46e-04	223	51	5	int:ERG
Interaction	KLF3 interactions	TAF3 SMARCA2 KAT2A TAF4 MBD6	2.73e-04	228	51	5	int:KLF3
Interaction	KIT interactions	CISH ABL1 FIZ1 TP53	2.81e-04	125	51	4	int:KIT
Interaction	ELF1 interactions	TAF3 SMARCA2 KAT2A TAF4	2.90e-04	126	51	4	int:ELF1
Interaction	PAX9 interactions	MAML1 SMARCA2 C15orf39 BCL9	3.27e-04	130	51	4	int:PAX9
Interaction	EYA4 interactions	BICRA MAML1 C15orf39 BCL9 SF1	3.66e-04	243	51	5	int:EYA4
Interaction	POLR2A interactions	CDKN1C ABL1 SMARCA2 TAF4 CABIN1 TP53 SCAF4	3.80e-04	536	51	7	int:POLR2A
Interaction	PCDHB11 interactions	MANEAL EMILIN2 MAP7	3.85e-04	56	51	3	int:PCDHB11
Interaction	ZFP41 interactions	UBE2O PRRC2C SF1	4.06e-04	57	51	3	int:ZFP41
Interaction	TBP interactions	TAF3 SMARCA2 POU2F2 TAF4 TP53	4.40e-04	253	51	5	int:TBP
Interaction	RBPJ interactions	PTF1A MAML1 MAML2 KAT2A TP53	4.48e-04	254	51	5	int:RBPJ
Interaction	XRCC6 interactions	UBE2O ABL1 CNTNAP1 POU2F2 KAT2A MBD6 HCFC1 SF1 TP53	4.76e-04	928	51	9	int:XRCC6
Interaction	SUPT3H interactions	KAT2A TAF4 TP53	4.95e-04	61	51	3	int:SUPT3H
Interaction	TAF1 interactions	TAF3 SMARCA2 TAF4 TP53 CDC42EP1	4.98e-04	260	51	5	int:TAF1
Interaction	CTBP1 interactions	MAML1 C15orf39 MAML2 KAT2A SF1 TP53	5.39e-04	406	51	6	int:CTBP1
Cytoband	17q21	MYL4 CNTNAP1 KAT2A	5.19e-05	63	52	3	17q21
GeneFamily	ATAC complex	KAT2A HCFC1	2.19e-04	13	31	2	1058
GeneFamily	Myosin light chains\|EF-hand domain containing	MYL1 MYL4	2.56e-04	14	31	2	657
Coexpression	FIGUEROA_AML_METHYLATION_CLUSTER_1_UP	CISH TAF3 MYL4 ZFHX2 MAP7	4.39e-06	122	52	5	M2159
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBML5	CASKIN1 APC2 CPEB3 ZFHX2 POU2F2 BSN RPH3A	3.55e-05	465	52	7	M39066
Coexpression	GSE5503_LIVER_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_UP	CISH PRR36 PRRC2C MBD6 ARHGAP33	4.67e-05	199	52	5	M6992
Coexpression	QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45_7DY_PREDICTIVE	MYL4 CPEB3 EMILIN2	5.46e-05	37	52	3	M40913
Coexpression	THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN	CDKN1C ABL1 BICRA C15orf39 KAT2A MBD6 HCFC1 SF1 ARHGAP33	6.49e-05	905	52	9	M40865
Coexpression	HALLMARK_WNT_BETA_CATENIN_SIGNALING	MAML1 KAT2A TP53	8.00e-05	42	52	3	M5895
Coexpression	PARK_HSC_AND_MULTIPOTENT_PROGENITORS	FIZ1 KAT2A TP53	9.85e-05	45	52	3	M1456
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal-interneuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UNCX CNTNAP1 ABHD8 BSN RPH3A	2.54e-06	186	52	5	d1d01ce46e62944aa9864eda47e8401b5f0d2bdc
ToppCell	facs-Brain_Non-Myeloid-Striatum_-18m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UNCX CNTNAP1 WIPF3 BSN RPH3A	2.75e-06	189	52	5	3d838da870623a6a278ddc8e6cedca85d9877e50
ToppCell	droplet-Thymus-nan-18m-Lymphocytic-Double_negative_Thymocyte,_DN4_(Cd8-,_Cd4-),_some_undergoing_VDJ_recombination_\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CNTNAP1 STK39 ABHD8 MAML2 TP53	2.82e-06	190	52	5	8f5e71a0861ee4e8f3ce45e8a7f18fb9d6036a3c
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-Mes-Like-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PRR36 MANEAL ZFHX2 SEMA4G	7.78e-06	108	52	4	d620f07243c2628494e689bbfabc14c453f4b1f4
ToppCell	E16.5-samps-Mesenchymal-Myofibroblast-myofibroblast_-_smooth_muscle-like\|E16.5-samps / Age Group, Lineage, Cell class and subclass	BICRA HES7 CPEB3 KAT2A	1.72e-05	132	52	4	9633653dba1edee47d915212fb6e68426da49de5
ToppCell	390C-Epithelial_cells-Epithelial-H_(AT1)\|390C / Donor, Lineage, Cell class and subclass (all cells)	CDKN1C WIPF3 FGD6 SEMA4G	3.65e-05	160	52	4	830f17bad94de05612fe6d53d39e42a4b3f3e2f3
ToppCell	390C-Epithelial_cells-Epithelial-H_(AT1)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	CDKN1C WIPF3 FGD6 SEMA4G	3.65e-05	160	52	4	18ae6822915d16699beb9047baeef9b006901a35
ToppCell	10x5'-blood-Lymphocytic_Invariant-Inducer-like-ILC3\|blood / Manually curated celltypes from each tissue	PRR36 FIZ1 CPEB3 MAP7	4.12e-05	165	52	4	f012a27ece54c0f7b73a2f4f89c6ee8b865f8782
ToppCell	PND01-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYL1 MYL4 OBSCN ZFHX2	4.21e-05	166	52	4	9a341dc7b756252caeaac1e934384911c880a634
ToppCell	PND01-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC-ASMC_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYL1 MYL4 OBSCN ZFHX2	4.21e-05	166	52	4	390cf5e56b72fcaf3b8520930bd35a3e3e173711
ToppCell	droplet-Heart-HEART_(ALL_4:4:4:1:1)-30m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYL1 MYL4 OBSCN CPEB3	4.62e-05	170	52	4	615cf9639c66b3fbd984ebe3f345280005d3c38a
ToppCell	droplet-Heart-HEART_(ALL_4:4:4:1:1)-30m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYL1 MYL4 OBSCN CPEB3	4.62e-05	170	52	4	d99f61aa85ea3f775165cb433421e6f1cda4f96b
ToppCell	facs-Skin-nan-24m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TGFB1I1 CDKN1C SALL3 ZFHX2	5.18e-05	175	52	4	f1166b567bca80dac3abe90c3dc544c831006640
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TGFB1I1 CDKN1C IER5L CNTNAP1	5.41e-05	177	52	4	452ec2df36c6d656a7cdadc55be545ccdb146a29
ToppCell	droplet-Marrow-BM_(NON-STC)-30m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UBE2O PRRC2C EMILIN2 POU2F2	5.53e-05	178	52	4	1a578d16008a450c42e73a996247ffecdc2c43f0
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYL1 MYL4 OBSCN BCL9	5.90e-05	181	52	4	09a574a3257e25c8b05a2ab20623a6b07331411a
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYL1 MYL4 OBSCN BCL9	5.90e-05	181	52	4	ac4142aa93706b7067f63d2d38e2456859e60768
ToppCell	facs-Brain_Non-Myeloid-Striatum_-18m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UNCX CNTNAP1 BSN RPH3A	6.69e-05	187	52	4	ef3c85c01bc3da408ae288b6e3096ad888a12e63
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Neuronal-interneuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UNCX CNTNAP1 BSN RPH3A	6.69e-05	187	52	4	1b2fdbfb1ce3f19795dfc4b1da5a94f4b057ec41
ToppCell	droplet-Thymus-nan-18m-Lymphocytic-double_negative_T_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STK39 ABHD8 MAML2 TP53	7.12e-05	190	52	4	84265be128170cbb08d76e824aa108e07da9c3e5
ToppCell	Influenza_Severe-Non-classical_Monocyte\|Influenza_Severe / Disease group and Cell class	CDKN1C IER5L C15orf39 POU2F2	7.27e-05	191	52	4	197edf6feb1cfc71d88e532d74f77305a42a3486
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UNCX CNTNAP1 BSN RPH3A	7.56e-05	193	52	4	5fb7808dd971c1cc64c2bd4f8f1de646fb2d77f4
ToppCell	severe_influenza-Non-classical_Monocyte\|severe_influenza / disease group, cell group and cell class (v2)	CDKN1C IER5L C15orf39 POU2F2	7.72e-05	194	52	4	7630e223666fb65743e21e045478f687dd739a54
ToppCell	distal-Hematologic-Nonclassical_Monocyte\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C C15orf39 POU2F2 RPH3A	7.87e-05	195	52	4	6f417bb464b8ae6a50bbab5db5a6d5760c02122f
ToppCell	distal-3-Hematologic-Nonclassical_Monocyte\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C C15orf39 POU2F2 RPH3A	8.03e-05	196	52	4	c1f3334bc09f5d0cfb9d998a3a64f0700426a357
ToppCell	COVID-19_Severe-Myeloid-Non-classical_Monocyte\|COVID-19_Severe / Disease group, lineage and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.19e-05	197	52	4	c5837b9a5a39a0f607a4e217ade9fc87d82a5406
ToppCell	COVID-19_Severe-Non-classical_Monocyte\|World / disease group, cell group and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.19e-05	197	52	4	60fee75b12451206bb2c07b61651a73c59ec6ade
ToppCell	distal-Hematologic-Nonclassical_Monocyte-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CDKN1C C15orf39 POU2F2 RPH3A	8.19e-05	197	52	4	e817c1a8549e403e723b1b6c73cdb04f1179909d
ToppCell	5'-GW_trimst-1-SmallIntestine-Neuronal-neurons_A\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MANEAL APC2 POU2F2 RPH3A	8.19e-05	197	52	4	a07e1a9b95c9f8a09452cbfe5a9f06648f66e29e
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	9b8679b3dd8f4220d71f607b7080cb88d6e71129
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	8b6b602ebe59b6dca6a22f17385d3160ff3ac67e
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	5436c3ed16e10e00c686f1ab0b0a68728a1a9985
ToppCell	COVID-19_Moderate-Non-classical_Monocyte\|World / disease group, cell group and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	8449934e20bb2a34079fb642cae0d4647b9efe51
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	b9030390316baf456135f85f831394e1e11ecf3e
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	4f67067d8142ca11b2d80195dac8d62a8d24d52c
ToppCell	PBMC-Severe-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CDKN1C EMILIN2 C15orf39 POU2F2	8.35e-05	198	52	4	d36a3cda7e5f385d2391e9b0dfb027d3c4549320
ToppCell	Parenchymal-10x5prime-Immune_Myeloid-Monocytic-Monocyte_CD16\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CDKN1C EMILIN2 C15orf39 POU2F2	8.68e-05	200	52	4	83d9aa5b46ae7a71a258b2e44b3251f95bc9a1b7
ToppCell	COVID-19-COVID-19_Severe-Myeloid-CD16+_Monocyte\|COVID-19_Severe / Disease, condition lineage and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.68e-05	200	52	4	58fbb7fc7159cbc417e6b457d60b7beba9b90da6
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-6m-Mesenchymal-Mesoderm\|6m / Sample Type, Dataset, Time_group, and Cell type.	CDKN1C MYL1 MYL4 WIPF3	8.68e-05	200	52	4	0f6851baf0cf2a8b0c95a7a585c4407c330c5f6c
ToppCell	severe-Non-classical_Monocyte\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.68e-05	200	52	4	6cc7190a4ffc6c06335072f3b5b5f98eae36e2ce
ToppCell	mild-Non-classical_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	CDKN1C EMILIN2 C15orf39 POU2F2	8.68e-05	200	52	4	334bab6bf93d455f3526e817ea5785d8b6ee531c
ToppCell	Influenza-Influenza_Severe-Myeloid-CD16+_Monocyte\|Influenza_Severe / Disease, condition lineage and cell class	CDKN1C IER5L C15orf39 POU2F2	8.68e-05	200	52	4	1efdcfcd86e99fbe03db19a2a5ab10808eec282d
ToppCell	droplet-Heart-4Chambers-21m-Hematologic-erythrocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UBE2O MYL4 SALL3	8.91e-05	74	52	3	6f222ebf7cb106bbb2ae3fb3cda660dfec3ea5d0
Drug	Trimethoprim [738-70-5]; Down 200; 13.8uM; PC3; HT_HG-U133A	CDKN1C MYL4 ABHD8 MAP7 CABIN1 HCFC1 CDC42EP1	3.03e-07	196	52	7	7377_DN
Drug	Piromidic acid [19562-30-2]; Down 200; 13.8uM; MCF7; HT_HG-U133A	PRR36 MAML1 SMARCA2 MAP7 BCL9 HCFC1 CDC42EP1	3.14e-07	197	52	7	3335_DN
Drug	Methimazole [60-56-0]; Down 200; 35uM; PC3; HT_HG-U133A	CDKN1C MYL4 ZFHX2 C15orf39 RPH3A ARHGAP33	4.76e-06	191	52	6	3815_DN
Drug	Decamethonium bromide [541-22-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	TGFB1I1 MYL4 PRR36 CPEB3 HCFC1 RPH3A	5.21e-06	194	52	6	4174_DN
Drug	Benfotiamine [22457-89-2]; Up 200; 8.6uM; PC3; HT_HG-U133A	MYL4 CPEB3 POU2F2 TAF4 HCFC1 CDC42EP1	5.36e-06	195	52	6	4312_UP
Drug	Dicyclomine hydrochloride [67-92-5]; Down 200; 11.6uM; PC3; HT_HG-U133A	CISH CDKN1C MYL4 ABHD8 SF1 ARHGAP33	5.36e-06	195	52	6	4581_DN
Drug	Levonordefrin [829-74-3]; Down 200; 21.8uM; MCF7; HT_HG-U133A	SMARCA2 C15orf39 KAT2A BCL9 CABIN1 SF1	5.68e-06	197	52	6	7208_DN
Drug	Propidium iodide [25535-16-4]; Up 200; 6uM; MCF7; HT_HG-U133A	MYL4 MAML1 POU2F2 KAT2A RPH3A ARHGAP33	5.68e-06	197	52	6	6277_UP
Drug	Talampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; MCF7; HT_HG-U133A	MYL4 ZFHX2 CABIN1 HCFC1 SF1 CDC42EP1	5.68e-06	197	52	6	7014_UP
Drug	genistein; Down 200; 10uM; MCF7; HT_HG-U133A_EA	BICRA PRRC2C C15orf39 KAT2A BCL9 SF1	5.68e-06	197	52	6	1015_DN
Drug	Methantheline bromide [53-46-3]; Down 200; 9.6uM; HL60; HT_HG-U133A	CDKN1C MYL4 BICRA CPEB3 ZFHX2 SEMA4G	5.85e-06	198	52	6	6137_DN
Drug	Meclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; PC3; HT_HG-U133A	CISH ZFHX2 CABIN1 HCFC1 SF1 SEMA4G	5.85e-06	198	52	6	2128_UP
Drug	Vancomycin hydrochloride [1404-93-9]; Up 200; 2.6uM; HL60; HT_HG-U133A	APC2 ZFHX2 POU2F2 MAP7 CABIN1 SEMA4G	6.02e-06	199	52	6	2498_UP
Drug	Thiosemicarbazones	CDKN1C ABL1 SMARCA2 TP53	1.39e-05	64	52	4	ctd:D013882
Drug	AC1NUKW9	ABL1 TP53	3.06e-05	4	52	2	CID005481610
Drug	Ethisterone [434-03-7]; Up 200; 12.8uM; PC3; HT_HG-U133A	MYL4 CPEB3 POU2F2 HCFC1 SF1	7.63e-05	192	52	5	4340_UP
Drug	PD 144795	CABIN1 TP53	7.63e-05	6	52	2	CID005481003
Drug	Beta-Escin [11072-93-8]; Down 200; 3.2uM; PC3; HT_HG-U133A	CDKN1C HCFC1 RPH3A SEMA4G SCAF4	8.01e-05	194	52	5	3807_DN
Drug	Clobetasol propionate [25122-46-7]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MYL4 PRR36 MAML1 HCFC1 SF1	8.01e-05	194	52	5	6835_UP
Drug	valinomycin; Down 200; 0.1uM; PC3; HT_HG-U133A	CDKN1C POU2F2 BCL9 HCFC1 ARHGAP33	8.21e-05	195	52	5	5911_DN
Drug	Apramycin [37321-09-8]; Down 200; 7.4uM; PC3; HT_HG-U133A	MYL4 SMARCA2 MAP7 BCL9 CABIN1	8.21e-05	195	52	5	6614_DN
Drug	Ramipril [87333-19-5]; Up 200; 9.6uM; PC3; HT_HG-U133A	CDKN1C MYL4 ABHD8 CABIN1 CDC42EP1	8.21e-05	195	52	5	7144_UP
Drug	Thioperamide maleate [106243-16-7]; Up 200; 9.8uM; HL60; HT_HG-U133A	TGFB1I1 CDKN1C MYL4 APC2 HCFC1	8.41e-05	196	52	5	3055_UP
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	MYL4 ZFHX2 CABIN1 HCFC1 CDC42EP1	8.41e-05	196	52	5	5568_DN
Drug	Graveoline [485-61-0]; Down 200; 14.4uM; PC3; HT_HG-U133A	CDKN1C MYL4 BICRA CNTNAP1 CABIN1	8.41e-05	196	52	5	4276_DN
Drug	Sulindac [38194-50-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A	MYL4 KAT2A MAP7 CABIN1 SCAF4	8.41e-05	196	52	5	5528_DN
Drug	Hydrochlorothiazide [58-93-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A	CDKN1C ZFHX2 POU2F2 CABIN1 SEMA4G	8.41e-05	196	52	5	4970_UP
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	TGFB1I1 MAML1 C15orf39 BCL9 CDC42EP1	8.61e-05	197	52	5	4751_DN
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A	PRR36 BICRA C15orf39 SEMA4G SCAF4	8.61e-05	197	52	5	1810_DN
Drug	Hydroflumethiazide [135-09-1]; Down 200; 12uM; PC3; HT_HG-U133A	CISH PRR36 MAP7 SCAF4 CDC42EP1	8.61e-05	197	52	5	1809_DN
Drug	U-62066 [87151-85-7]; Down 200; 1uM; PC3; HT_HG-U133A	CISH CDKN1C CABIN1 SEMA4G ARHGAP33	8.61e-05	197	52	5	3818_DN
Drug	Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A	TGFB1I1 PRR36 BICRA MAML1 HCFC1	8.61e-05	197	52	5	3829_DN
Drug	Acebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A	CDKN1C SMARCA2 POU2F2 SEMA4G ARHGAP33	8.61e-05	197	52	5	4976_UP
Drug	alpha-estradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A	PRR36 MAML1 C15orf39 CABIN1 HCFC1	8.61e-05	197	52	5	1635_DN
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A	CDKN1C MYL4 ZFHX2 SF1 ARHGAP33	8.61e-05	197	52	5	4477_DN
Drug	clozapine; Up 200; 10uM; HL60; HT_HG-U133A	TGFB1I1 CDKN1C MAP7 RPH3A SEMA4G	8.61e-05	197	52	5	2689_UP
Drug	Pseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; MCF7; HT_HG-U133A	MYL4 PRR36 BCL9 HCFC1 ARHGAP33	8.61e-05	197	52	5	2766_UP
Drug	Allantoin [97-59-6]; Down 200; 25.2uM; PC3; HT_HG-U133A	CISH PRR36 C15orf39 CABIN1 SEMA4G	8.82e-05	198	52	5	1800_DN
Drug	Betazole hydrochloride; Down 200; 27uM; MCF7; HT_HG-U133A	CISH SMARCA2 C15orf39 BCL9 CABIN1	8.82e-05	198	52	5	1690_DN
Drug	PHA-00745360 [351320-33-7]; Up 200; 1uM; PC3; HT_HG-U133A	CISH SMARCA2 POU2F2 ARHGAP33 SCAF4	8.82e-05	198	52	5	4562_UP
Drug	Bromopride [4093-35-0]; Down 200; 11.6uM; MCF7; HT_HG-U133A	MYL4 POU2F2 HCFC1 SCAF4 CDC42EP1	8.82e-05	198	52	5	3617_DN
Drug	Dimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; MCF7; HT_HG-U133A	TGFB1I1 PRR36 KAT2A ARHGAP33 SCAF4	8.82e-05	198	52	5	4791_DN
Drug	Delsoline [509-18-2]; Up 200; 8.6uM; PC3; HT_HG-U133A	CDKN1C POU2F2 MAP7 HCFC1 SCAF4	8.82e-05	198	52	5	5858_UP
Drug	Asiaticoside [16830-15-2]; Down 200; 4.2uM; PC3; HT_HG-U133A	CDKN1C MYL4 C15orf39 HCFC1 CDC42EP1	8.82e-05	198	52	5	7244_DN
Drug	Cefotetan [69712-56-7]; Down 200; 7uM; HL60; HT_HG-U133A	CISH UBE2O BICRA KAT2A SF1	9.03e-05	199	52	5	1319_DN
Drug	Ungerine nitrate; Up 200; 10.2uM; HL60; HT_HG-U133A	CNTNAP1 POU2F2 FGD6 HCFC1 ARHGAP33	9.03e-05	199	52	5	2514_UP
Drug	3-nitropropionic acid; Up 200; 10uM; PC3; HT_HG-U133A	CISH MYL4 BICRA APC2 BCL9	9.03e-05	199	52	5	6407_UP
Drug	Bethanechol chloride [590-63-6]; Down 200; 20.4uM; MCF7; HT_HG-U133A	MYL4 C15orf39 KAT2A FGD6 HCFC1	9.03e-05	199	52	5	5539_DN
Drug	Doxazosin mesylate [77883-43-3]; Up 200; 7.4uM; MCF7; HT_HG-U133A	MYL4 PRR36 ZFHX2 CABIN1 RPH3A	9.03e-05	199	52	5	4988_UP
Drug	Adrenosterone [382-45-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A	TGFB1I1 CISH KAT2A CABIN1 FGD6	9.03e-05	199	52	5	5464_DN
Drug	SB 202190; Up 200; 1uM; PC3; HT_HG-U133A	CDKN1C CNTNAP1 ABHD8 SEMA4G SCAF4	9.03e-05	199	52	5	7058_UP
Drug	(cis-) Nanophine [5072-45-7]; Down 200; 26.8uM; PC3; HT_HG-U133A	SMARCA2 MAP7 HCFC1 SEMA4G SCAF4	9.03e-05	199	52	5	4543_DN
Drug	Condelphine [7633-69-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A	CNTNAP1 CPEB3 ARHGAP33 SCAF4 CDC42EP1	9.25e-05	200	52	5	3538_UP
Drug	CP-320650-01 [172079-28-6]; Down 200; 10uM; MCF7; HT_HG-U133A	MYL4 PRR36 CNTNAP1 POU2F2 CDC42EP1	9.25e-05	200	52	5	4379_DN
Drug	Carbarsone [121-59-5]; Down 200; 15.4uM; PC3; HT_HG-U133A	CDKN1C MYL4 C15orf39 CABIN1 HCFC1	9.25e-05	200	52	5	3991_DN
Drug	1-benzothiophene-2-carboxamide	CABIN1 TP53	1.07e-04	7	52	2	CID000237073
Drug	ethyl-2,5-dihydroxycinnamate	ABL1 TP53	2.28e-04	10	52	2	CID006441630
Drug	AC1MIX0P	MYL1 CNTNAP1 POU2F2	2.57e-04	54	52	3	CID003081487
Drug	AC1NBK95	ABL1 CNTNAP1	6.01e-04	16	52	2	CID004469365
Drug	bromfenacoum	TAF3 CASKIN1 CNTNAP1 CPEB3 BSN HCFC1 CDC42EP1	6.21e-04	644	52	7	ctd:C013418
Drug	Mefloquine hydrochloride [51773-92-3]; Up 200; 9.6uM; PC3; HT_HG-U133A	CDKN1C MYL4 PRR36 ZFHX2	7.30e-04	178	52	4	2048_UP
Drug	Carmustine	CDKN1C APC2 CNTNAP1 HCFC1 SF1 TP53	7.96e-04	484	52	6	ctd:D002330
Drug	Cantharidin [56-25-7]; Down 200; 20.4uM; HL60; HT_HG-U133A	C15orf39 MAP7 SF1 SCAF4	8.77e-04	187	52	4	3075_DN
Drug	Forskolin, from Coleus forskohlii; Up 200; 0.5uM; PC3; HT_HG-U133A	CISH MYL4 ZFHX2 MAP7	8.94e-04	188	52	4	7104_UP
Drug	nickel subsulfide	TGFB1I1 CDKN1C MYL1 TP53	8.94e-04	188	52	4	ctd:C017557
Drug	pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A	CDKN1C ZFHX2 FGD6 HCFC1	9.30e-04	190	52	4	7528_DN
Drug	NCI60_002052	ABL1 TP53	9.47e-04	20	52	2	CID006801032
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	CDKN1C PRR36 MAML1 RPH3A	9.49e-04	191	52	4	3975_DN
Drug	Calciferol [50-14-6]; Down 200; 10uM; PC3; HT_HG-U133A	CISH MYL4 ABHD8 SCAF4	9.49e-04	191	52	4	6746_DN
Drug	0393-0188; Up 200; 10uM; PC3; HT_HG-U133A	CISH MYL4 BCL9 HCFC1	9.67e-04	192	52	4	7536_UP
Drug	Dihydroergotoxine mesylate [8067-24-1]; Down 200; 6.4uM; MCF7; HT_HG-U133A	MYL4 PRR36 BCL9 CDC42EP1	9.67e-04	192	52	4	4152_DN
Drug	Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A	PRR36 ZFHX2 CABIN1 HCFC1	9.67e-04	192	52	4	2807_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A	CISH UBE2O HCFC1 SEMA4G	9.67e-04	192	52	4	1971_DN
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A	MYL4 HCFC1 RPH3A SCAF4	9.86e-04	193	52	4	3627_DN
Drug	0316684-0000 [391209-55-5]; Up 200; 10uM; PC3; HT_HG-U133A	CDKN1C CNTNAP1 SEMA4G SCAF4	9.86e-04	193	52	4	7057_UP
Drug	Ergocryptine-alpha [511-09-1]; Up 200; 7uM; MCF7; HT_HG-U133A	MYL4 SMARCA2 MAP7 SEMA4G	9.86e-04	193	52	4	3434_UP
Drug	troglitazone; Up 200; 10uM; MCF7; HT_HG-U133A	MYL4 ZFHX2 BCL9 SCAF4	9.86e-04	193	52	4	1657_UP
Drug	Resveratrol [501-36-0]; Up 200; 17.6uM; HL60; HG-U133A	ABL1 POU2F2 HCFC1 SCAF4	9.86e-04	193	52	4	1715_UP
Drug	Tetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; MCF7; HT_HG-U133A	MYL4 CPEB3 ARHGAP33 CDC42EP1	9.86e-04	193	52	4	2748_UP
Drug	Nadide [53-84-9]; Up 200; 6uM; PC3; HT_HG-U133A	SMARCA2 MAP7 BCL9 CABIN1	1.01e-03	194	52	4	5873_UP
Drug	Pridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A	SMARCA2 C15orf39 BCL9 CABIN1	1.01e-03	194	52	4	7214_DN
Drug	Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	MYL4 POU2F2 SEMA4G ARHGAP33	1.01e-03	194	52	4	4961_UP
Drug	Pyridoxine hydrochloride [58-56-0]; Up 200; 19.4uM; HL60; HG-U133A	UBE2O ABL1 HCFC1 ARHGAP33	1.01e-03	194	52	4	1759_UP
Drug	pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A	CDKN1C MYL4 ZFHX2 CABIN1	1.01e-03	194	52	4	6893_DN
Drug	Tridihexethyl chloride; Up 200; 11.4uM; MCF7; HT_HG-U133A	PRR36 BICRA HCFC1 ARHGAP33	1.01e-03	194	52	4	3526_UP
Drug	Chlorzoxazone [95-25-0]; Up 200; 23.6uM; PC3; HT_HG-U133A	CISH ZFHX2 CABIN1 HCFC1	1.01e-03	194	52	4	2100_UP
Drug	Methoxy-8-psoralen [298-81-7]; Up 200; 18.6uM; MCF7; HT_HG-U133A	MYL4 ZFHX2 CABIN1 ARHGAP33	1.01e-03	194	52	4	3302_UP
Drug	Pirenperone [ 75444-65-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A	CISH SMARCA2 CABIN1 SCAF4	1.01e-03	194	52	4	3316_DN
Drug	Nadolol [42200-33-9]; Up 200; 13uM; PC3; HT_HG-U133A	KAT2A BCL9 HCFC1 SCAF4	1.01e-03	194	52	4	4021_UP
Drug	Trihexyphenidyl-D,L Hydrochloride [58947-95-8]; Up 200; 11.8uM; PC3; HT_HG-U133A	ZFHX2 TP53 ARHGAP33 SCAF4	1.01e-03	194	52	4	4015_UP
Drug	Scoulerine [6451-73-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	CISH MYL4 BCL9 SCAF4	1.01e-03	194	52	4	2891_DN
Drug	Benzethonium chloride [121-54-0]; Down 200; 9uM; MCF7; HT_HG-U133A	MYL4 MAML1 BCL9 CABIN1	1.01e-03	194	52	4	6070_DN
Drug	Graveoline [485-61-0]; Up 200; 14.4uM; PC3; HT_HG-U133A	MYL4 BICRA POU2F2 ARHGAP33	1.01e-03	194	52	4	3716_UP
Drug	Mebendazole [31431-39-7]; Down 200; 13.6uM; PC3; HT_HG-U133A	CISH C15orf39 BCL9 SEMA4G	1.01e-03	194	52	4	3671_DN
Drug	Cyclacillin [3485-14-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	MYL4 MAML1 ARHGAP33 CDC42EP1	1.02e-03	195	52	4	4358_DN
Drug	5140203; Down 200; 15uM; MCF7; HT_HG-U133A_EA	TBC1D10B PRR36 CABIN1 CDC42EP1	1.02e-03	195	52	4	908_DN
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A	CISH CDKN1C ABHD8 CDC42EP1	1.02e-03	195	52	4	5117_DN
Drug	Dimaprit dihydrochloride [23256-33-9]; Down 200; 17uM; MCF7; HT_HG-U133A	MYL4 C15orf39 CABIN1 SCAF4	1.02e-03	195	52	4	7480_DN
Drug	Furaltadone hydrochloride [3759-92-0]; Up 200; 11uM; PC3; HT_HG-U133A	MYL4 MAML1 HCFC1 SF1	1.02e-03	195	52	4	4313_UP
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Up 200; 14uM; MCF7; HT_HG-U133A	PRR36 CNTNAP1 C15orf39 HCFC1	1.02e-03	195	52	4	2805_UP
Disease	Burkitt Lymphoma	ABL1 SALL3 TP53	3.54e-05	36	52	3	C0006413
Disease	B-lymphoblastic leukemia/lymphoma (is_implicated_in)	ABL1 TP53	1.36e-04	10	52	2	DOID:0080630 (is_implicated_in)
Disease	Hypertrophic Cardiomyopathy	MYL4 OBSCN TP53	1.41e-04	57	52	3	C0007194
Disease	response to 5-fluorouracil, response to cyclophosphamide, chemotherapy-induced alopecia, response to doxorubicin	SMARCA2 BCL9	2.73e-04	14	52	2	EFO_0005400, GO_0036275, GO_1902518, GO_1902520
Disease	caffeine measurement	STK39 MAML2	3.15e-04	15	52	2	EFO_0021177
Disease	mean reticulocyte volume	IER5L C15orf39 KAT2A TAF4 RPH3A SF1 TP53	4.82e-04	799	52	7	EFO_0010701
Disease	Precursor B-cell lymphoblastic leukemia	ABL1 TP53	6.26e-04	21	52	2	C1292769
Disease	response to antineoplastic agent	SMARCA2 RPH3A DMAC1	7.19e-04	99	52	3	GO_0097327
Disease	Hypertrophic obstructive cardiomyopathy	MYL4 TP53	8.90e-04	25	52	2	C4551472
Disease	Malignant mesothelioma	SMARCA2 FGD6 TP53	9.50e-04	109	52	3	C0345967
Disease	melanoma	CDKN1C ABL1 SF1 TP53	9.61e-04	248	52	4	C0025202
Disease	oral squamous cell carcinoma (is_implicated_in)	ABL1 TP53	1.12e-03	28	52	2	DOID:0050866 (is_implicated_in)
Disease	Carcinoma, Granular Cell	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0205644
Disease	Adenocarcinoma, Tubular	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0205645
Disease	Adenocarcinoma, Oxyphilic	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0205642
Disease	Carcinoma, Cribriform	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0205643
Disease	Adenocarcinoma, Basal Cell	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0205641
Disease	Adenocarcinoma	CDKN1C ABL1 TP53	1.14e-03	116	52	3	C0001418
Disease	central nervous system cancer, glioma	MAML2 TP53	1.20e-03	29	52	2	EFO_0000326, EFO_0005543
Disease	creatinine measurement	TBC1D10B UNCX PRRC2C OBSCN TAF4 BSN CDC42EP1	1.73e-03	995	52	7	EFO_0004518

Protein segments in the cluster

Peptide	Gene	Start	Entry
ATTPAPAPAPAPAPA	BARGIN	516	Q6ZT62
PAPAPAPAPAPALAS	BARGIN	521	Q6ZT62
PPGTAAAPAKPAPPA	DMAC1	16	Q96GE9
AAPAKPAPPATPGAP	DMAC1	21	Q96GE9
QAPASAPAPAPTPAP	CNTNAP1	1351	P78357
APSDPALPAPPPATA	CISH	191	Q9NSE2
VKHAGPAPAAAPPPP	ABHD8	46	Q96I13
TPTPAPAPAPAAAPA	KAT2A	41	Q92830
PANPPKSPAPAAAAP	HCFC1	421	P51610
QPPAATAPAPAAPAP	MAML1	76	Q92585
PSPARQPPAALAKPP	CASKIN1	1301	Q8WXD9
PAPPAASKAPVVPSP	MBD6	476	Q96DN6
PAPASAPAPASAPAP	MAP7	431	Q14244
APAPASAPAPAPVPT	MAP7	436	Q14244
PAPAPLAGQKPPADA	BSN	2326	Q9UPA5
DSAPAAPLPPQPAQP	POU2F2	71	P09086
APAPAPAPAPAKPKE	MYL1	21	P05976
EAAKPAPAPAPAPAP	MYL4	11	P12829
APAAPTPAAPAPAPS	TP53	76	P04637
QPAPPAAPLALAPPS	PTF1A	71	Q7RTS3
PFLGQPQAPPAPAKA	OBSCN	7076	Q5VST9
PQAPPAPAKASPPLD	OBSCN	7081	Q5VST9
PPPPAAPPAASQAAA	MAML2	106	Q8IZL2
APPASPAPPAPASAF	ARHGAP33	756	O14559
KEAPAPSKAAPAAPP	APC2	1546	O95996
TPLTPAQPAPAPAPA	CABIN1	1811	Q9Y6J0
LSPAAAPPAPNGPDK	CPEB3	56	Q8NE35
AVLAPAPAPAPAPAP	CDKN1C	176	P49918
APAPVAAPAPAPAPA	CDKN1C	191	P49918
SNSSSADPKAPPPPP	BCL9	321	O00512
PAANPPATTANPPAP	CDC42EP1	241	Q00587
KPAPPPPPAASAGKA	ABL1	896	P00519
APTPAPAPPAAAAPR	FIZ1	6	Q96SL8
APAARAPAAPAAPPP	MANEAL	56	Q5VSG8
KFQPSAKAPSPPPPA	EMILIN2	781	Q9BXX0
QDGAPKAPLPPPPAF	HES7	206	Q9BYE0
APPPAQDPAPATPVA	BICRA	726	Q9NZM4
AAPAAASPPPPQAPF	SCAF4	306	O95104
PAAPSAAPAPAAPAP	SALL3	311	Q9BXA9
AAPAPAAPAPAPAPQ	SALL3	316	Q9BXA9
PPAAAASPPASPAPA	IER5L	216	Q5T953
APSQNRPKTPPPAPA	TAF3	786	Q5VWG9
AAAPPAPAAPSPPAA	TAF4	246	O00268
APAAPSPPAAPAPAA	TAF4	251	O00268
SPPAAPAPAAPAAAP	TAF4	256	O00268
AAAPQPAAARQPPPP	RPH3A	361	Q9Y2J0
RPSPAPPAAAQPPAA	SMARCA2	286	P51531
AASCPLPPAPPQKPS	FAM83E	286	Q2M2I3
SPLAKPPPQAPPALA	PRR36	1001	Q9H6K5
APAPAPTPVSAPNPA	PRRC2C	1911	Q9Y520
PPQKAGAQALPAPPA	WIPF3	336	A6NGB9
VASPAPAPAPSPAPA	C15orf39	716	Q6ZRI6
PAPAPSPAPARAQAP	C15orf39	721	Q6ZRI6
LAPAPEAPPALKAPP	ZFHX2	2191	Q9C0A1
RPATPAPAPKAPATP	SEMA4G	651	Q9NTN9
ANNKPAPPPIAPKPD	FGD6	21	Q6ZV73
APTPAAPAPAQAPAP	UBE2O	6	Q9C0C9
PAPAAAPVPAPAPAS	UBE2O	26	Q9C0C9
APAPAPAPAPAPAVT	TBC1D10B	71	Q4KMP7
PRSPKPAAPAAPPFS	TGFB1I1	66	O43294
APAAPAAPAPAPAPA	STK39	36	Q9UEW8
ASAPRPAAPANNPPP	SF1	341	Q15637
PAPAVPPAPPAQASF	UNCX	411	A6NJT0
FSPPPSKPRSPNPAA	KIAA1522	611	Q9P206